35197-64-9

Usage

Uses

Used in Pharmaceutical Drug Development:
2-Bromo-4-(1,3-dioxoisoindolin-2-yl)butanoic acid is utilized as a key intermediate in the synthesis of pharmaceutical drugs, particularly for the development of novel therapeutics targeting neurological disorders and cancer. Its unique structure and functional groups contribute to the design and synthesis of new drug candidates with improved efficacy and selectivity.
Used in Organic Synthesis:
In the field of organic chemistry, 2-Bromo-4-(1,3-dioxoisoindolin-2-yl)butanoic acid serves as a valuable building block for the synthesis of complex organic molecules. Its presence of a bromine atom and carboxylic acid group allows for various chemical reactions, facilitating the creation of diverse organic compounds with specific properties and applications.
Used in Medicinal Chemistry Research:
2-Bromo-4-(1,3-dioxoisoindolin-2-yl)butanoic acid is employed as a research tool in medicinal chemistry to explore its potential therapeutic applications. Studies are conducted to understand its interactions with biological targets and its effects on disease pathways, particularly in the context of neurological disorders and cancer. This research aids in the advancement of drug discovery and the development of more effective treatments.
Used in Drug Delivery Systems:
Although not explicitly mentioned in the provided materials, given its potential therapeutic applications, 2-Bromo-4-(1,3-dioxoisoindolin-2-yl)butanoic acid could also be incorporated into drug delivery systems. These systems could be designed to improve the bioavailability, targeting, and therapeutic outcomes of drugs containing 2-BroMo-4-(1,3-dioxoisoindolin-2-yl)butanoic acid, especially in the treatment of neurological disorders and cancer.

Upstream product

• 85-44-9 phthalic anhydride 
• 22509-74-6 N-ethoxycarbonylphthalimide 
• 108749-42-4 2-amino-4-phthalimido-butyric acid 
• 3130-75-4 4-phthalimidobutyric acid 

Downstream Products

• 40732-91-0 γ-phthalimidoimino-α-hydroxybutyric acid 
• 111441-97-5 2-bromo-4-phthalimido-butyric acid-(N-methyl-anilide) 
• 35294-53-2 methyl 2-bromo-4-(1,3-dioxoisoindolin-2-yl)butanoate 
• 128218-04-2 4-(6,7-Bis-benzyloxy-2-oxo-1,2-dihydro-imidazo[4,5-b]quinolin-3-yl)-butyric acid tert-butyl ester 
• 128217-95-8 2-[6,7-Bis-benzyloxy-3-(2,5-dioxo-pyrrolidin-1-yl)-2-oxo-3,4-dihydro-2H-quinolin-1-yl]-4-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-butyric acid methyl ester 
• 128217-89-0 2-(3-Allyloxycarbonylamino-6,7-bis-benzyloxy-2-oxo-3,4-dihydro-2H-quinolin-1-yl)-4-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-butyric acid tert-butyl ester 
• 128217-93-6 2-[6,7-Bis-benzyloxy-3-(2,5-dioxo-pyrrolidin-1-yl)-2-oxo-3,4-dihydro-2H-quinolin-1-yl]-4-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-butyric acid allyl ester 
• 128218-22-4 C₄₈H₅₁N₃O₁₁ 
• 17079-24-2 N-phthaloyl-δ-aminovaleric acid methyl ester 
• 100061-16-3 3-hydroxy-1-(2-nitro-benzyl)-pyrrolidin-2-one 
• 178933-30-7 Thioacetic acid S-{3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-1-[(S)-3-methyl-1-((S)-1-methylcarbamoyl-2-phenyl-ethylcarbamoyl)-butylcarbamoyl]-propyl} ester 
• 19532-96-8 N,N'-dibutylamide of phthalic acid 
• 38228-97-6 N¹,N²-diisopropylphthalamide 
• 99849-71-5 4-Amino-2-cyclohexylamino-buttersaeure 

Relevant academic research and scientific papers

Synthesis, biological evaluation and structure-activity relationship of new GABA uptake inhibitors, derivatives of 4-aminobutanamides

Six series of 2-substituted 4-aminobutanamide derivatives were synthesized and evaluated for their ability to inhibit GABA transport proteins mGAT1-4 stably expressed in HEK-293 cell lines. The pIC50 values determined were in the range 4.23-5.23. Two compounds (15b and 15c) were selected for further in vitro studies. These compounds were also subjected to preliminary behavioral studies to evaluate their anticonvulsant, antidepressant-like, and antinociceptive activities in mice. Their influence on motor coordination was also assessed. We report that, among a spectrum of in vivo activities, both 15b and 15c displayed significant activity against pentylenetetrazole (PTZ)-induced seizures.

Synthesis and characterization of novel phosphonocarboxylate inhibitors of RGGT

Phosphonocarboxylate (PC) analogs of the anti-osteoporotic drugs, bisphosphonates, represent the first class of selective inhibitors of Rab geranylgeranyl transferase (RabGGTase, RGGT), an enzyme implicated in several diseases including ovarian, breast and skin cancer. Here we present the synthesis and biological characterization of an extended set of this class of compounds, including lipophilic derivatives of the known RGGT inhibitors. From this new panel of PCs, we have identified an inhibitor of RGGT that is of similar potency as the most active published phosphonocarboxylate, but of higher selectivity towards prenyl pyrophosphate synthases. New insights into structural requirements are also presented, showing that only PC analogs of the most potent 3rd generation bisphosphonates inhibit RGGT. In addition, the first phosphonocarboxylate-derived GGPPS weak inhibitor is reported.

MATRIX METALLOPROTEINASE INHIBITORS

The present invention relates to methyl sulfonamides and N-formamides derivatives of formula (I) and to processes for their syntheses. The invention also relates to pharmacological compositions containing these derivatives and methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatie arthritis, psoriasis, pulmonary fibrosis, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, dry eye, neointimal proliferation which leads to restenosis and ischemic heart failure, stroke, renal disease, tumor metastasis, and other inflammatory disorders characterized by over expression and over activation of an matrix metalloproteinase using the compounds.

INHIBITORS OF CHECKPOINT KINASES

The instant invention provides for compounds which comprise substituted thioquinazolinones that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of treatment of cancer.

THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS

The present invention relates to compounds with the formula (I), wherein R1, R2, R3, X, and Y are as defined herein, and also to pharmaceutical compositions comprising the compounds, as well as to the use of the compounds in medicine and for the preparation of a medicament which acts on the human 11-β-hydroxysteroid dehydrogenase type 1 enzyme.

Mercaptoacyl matrix metalloproteinase inhibitors: The effect of substitution at the mercaptoacyl moiety

The in vitro potency of orally-active mercaptoacyl matrix metalloproteinase inhibitors is increased by the introduction of appropriate substitutents on the mercaptoacyl moiety.

Synthesis of the Chromophore of Pseudobactin, a Fluorescent Siderophore from Pseudomonas

Protected forms of dihydroxyphenylalanine (DOPA) were converted to the corresponding dihydroquinolin-2-ones 13 by nitration and reductive cyclization.Subsequent N-alkylation with α-halo-γ-aminobutyric acid derivatives provided the carbon framework 12 for the chromophore of pseudobactin.Conversion to protected forms of the fluorescent chromophore 5 was accomplished by reaction of 12 with Lawesson's reagent to produce the corresponding thioamide which was cyclized by reaction with mercuric acetate.